Concentration and integrity indexes of urine cell-free DNA as promising biomarkers for early lung cancer diagnosis

2021 ◽  
Vol 18 (2) ◽  
pp. 129-139
Author(s):  
Sai Ren ◽  
Xiaodong Ren ◽  
Haiqin Guo ◽  
Lan Liang ◽  
Kun Wei ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Characteristic Curve ◽  
Healthy Controls ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis ◽  
Free Dna ◽  
Pcr Targeting

Aim: To explore the role of urine cell-free DNA (ucfDNA) concentration and integrity indexes as potential biomarkers for lung cancer diagnosis. Materials & methods: Quantitative real-time PCR targeting Arthrobacter luteus ( ALU) repeats at three size fragments ( ALU-60, 115 and 247 bp) was performed in 55 lung cancer patients and 35 healthy individuals. Results: ucfDNA concentration and integrity indexes were significantly higher in lung cancer patients than in healthy controls. The area under the receiver operating characteristic curve for differentiating patients with stage I/II from healthy controls by ALU fragments concentration were 0.856, 0.909 and 0.932, respectively. In addition, the ucfDNA integrity indexes in patients with lymph node metastasis were significantly higher than in patients with non-metastatic. Conclusion: ucfDNA concentration and integrity indexes could serve as promising biomarkers for lung cancer diagnosis.

Feasibility Analysis of Cell-Free DNA Derived from Plasma of Lung Cancer Patients for Next-Generation Sequencing

2020 ◽  
Vol 18 (2) ◽  
pp. 117-121 ◽  
Author(s):  
Xueli Jiang ◽  
Hui Li ◽  
Jingjing Liu ◽  
Heping Sun ◽  
Linna Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Next Generation Sequencing ◽  
Cancer Patients ◽  
Feasibility Analysis ◽  
Next Generation ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Generation Sequencing

scholarly journals Dynamics of methylated cell-free DNA in the urine of non-small cell lung cancer patients

Epigenetics ◽  
2021 ◽  
pp. 1-13
Author(s):  
Sander Bach ◽  
Birgit M.M. Wever ◽  
Mark A. van de Wiel ◽  
Joris D. Veltman ◽  
Sayed M.S. Hashemi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Free Dna

scholarly journals Increased microRNA-30a levels in bronchoalveolar lavage fluid as a diagnostic biomarker for lung cancer

PeerJ ◽  
2021 ◽  
Vol 9 ◽  
pp. e11528
Author(s):  
Wen-Jun Zhu ◽  
Bo-Jiang Chen ◽  
Ying-Ying Zhu ◽  
Ling Sun ◽  
Yu-Chen Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Bronchoalveolar Lavage ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Roc Curve ◽  
Lung Diseases ◽  
Bronchoalveolar Lavage Fluid ◽  
Lavage Fluid ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Background MicroRNA-30a (miRNA-30a) levels have been shown to increase in the plasma of lung cancer patients. Herein, we evaluated the miRNA-30a levels in the bronchoalveolar lavage fluid (BALF) of lung cancer patients as a potential biomarker for lung cancer diagnosis. Methods BALF miRNA-30a expression of 174 subjects was quantified using quantitative real-time reverse transcription-polymerase chain reaction and compared between lung cancer patients and control patients with benign lung diseases. Moreover, its diagnostic value was evaluated by performing receiver operating characteristic (ROC) curve analysis. Results The relative BALF miRNA-30a expression was significantly higher in the lung cancer patients than in the controls (0.74 ±  0.55 versus 0.07 ±  0.48, respectively, p < 0.001) as well as in lung cancer patients with stage I–IIA disease than in those with stage IIB–IV disease (0.98 ±  0.64 versus 0.66 ±  0.54, respectively, p < 0.05). Additionally, miRNA-30a distinguished benign lung diseases from lung cancers, with an area under the ROC curve (AUC) of 0.822. ROC analysis also revealed an AUC of 0.875 for the Youden index-based optimal cut-off points for stage I–IIA adenocarcinoma. Thus, increased miRNA-30a levels in BALF may be a useful biomarker for non-small-cell lung cancer diagnosis.

scholarly journals Case study of an autoantibody panel for early detection of lung cancer and ground-glass nodules

2020 ◽  
Vol 146 (12) ◽  
pp. 3349-3357
Author(s):  
Yunli Huo ◽  
Zijian Guo ◽  
Xuehui Gao ◽  
Zhongjuan Liu ◽  
Ruili Zhang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Disease ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Positive Test ◽  
Test Results ◽  
Newly Diagnosed ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Abstract Purpose Increasing lung cancer incidence in China with a high death rate due to late diagnosis highlights the need for biomarkers, such as panels of autoantibodies (AAbs), for prediction and early lung cancer diagnosis. We conducted a study to further evaluate the clinical performance of an AAb diagnostic kit. Methods Using enzyme-linked immunosorbent assay, levels of seven AAbs in serum samples from 121 patients with newly diagnosed lung cancer, 84 controls (34 healthy individuals and 50 patients with benign lung disease), and 100 indeterminate solid nodules, were measured. Participants were followed up until 6 months after a positive test result to confirm lung cancer diagnosis. Results The seven AAb concentration was significantly higher in lung cancer patients than in controls (P < 0.05). The seven AAb sensitivity and specificity for newly diagnosed lung cancer were 45.5% and 85.3%, respectively, while the seven AAb combined area under the curve (in lung cancer patients versus controls) was 0.660. Of the 28 patients with solid nodules with positive test results, 8 and 3 were diagnosed with lung cancer and benign lung disease, respectively, during follow-up. The positive predictive value of the experiment was 72.7%. Conclusion Positive AAb test results were associated with a high risk of lung cancer. The seven-AAb panel also had a high predictive value for detecting lung cancer in patients with solid nodules. Our seven lung cancer autoantibody types can provide an important early warning sign in the clinical setting.

scholarly journals EP-1368 Circulating cell free DNA during chemoradiotherapy in non-small cell lung cancer patients

2019 ◽  
Vol 133 ◽  
pp. S747-S748
Author(s):  
L. Nygaard ◽  
L. Ahlborn ◽  
G. Persson ◽  
D. Chandrananda ◽  
J. Langer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cancer Patients ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Free Dna ◽  
Lung Cancer Patients ◽  
Free Dna ◽  
Circulating Cell Free Dna
Sign in / Sign up

Export Citation Format

Share Document